Trial Search Results
Characterization of Treatment Responses in Lymphedema
This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of clinical responses (changes in limb volume and skin thickness) with changes in the inflammasome will help to define the molecular substrate of treatment response.
Stanford is currently accepting patients for this trial.
- Drug: Ketoprofen
- Participants with a history of acquired lymphedema
- Stage 1, 2, or 3
- 18-75 years
- Clinical use of ketoprofen for lymphedema
- Active cancer, infection, bleeding tendency, inflammatory disease and/or taking
anti-inflammatory or anti-leukotriene medication will be excluded.
- Pregnant or lactating females
- Inability to take ketoprofen (contra-indicated, e.g patients with known CV, GI, renal,
- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation, may
interfere with interpretation of study results, and in the judgement of the
investigator, would make the participation inappropriate for entry into this study.
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study